Salarius Pharmaceuticals SLRX Stock
Salarius Pharmaceuticals Price Chart
Salarius Pharmaceuticals SLRX Financial and Trading Overview
| Salarius Pharmaceuticals stock price | 0.73 USD |
| Previous Close | 1.47 USD |
| Open | 1.46 USD |
| Bid | 1.45 USD x 100 |
| Ask | 1.52 USD x 100 |
| Day's Range | 1.44 - 1.5 USD |
| 52 Week Range | 1.26 - 7.27 USD |
| Volume | 25.68K USD |
| Avg. Volume | 356.78K USD |
| Market Cap | 2.16M USD |
| Beta (5Y Monthly) | 0.932 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.79 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26 USD |
SLRX Valuation Measures
| Enterprise Value | -1111087 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.16357689 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.40485832 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.165 |
Trading Information
Salarius Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.932 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 7.27 USD |
| 52 Week Low | 1.26 USD |
| 50-Day Moving Average | 1.58 USD |
| 200-Day Moving Average | 3.06 USD |
SLRX Share Statistics
| Avg. Volume (3 month) | 356.78K USD |
| Avg. Daily Volume (10-Days) | 55.93K USD |
| Shares Outstanding | 1.44M |
| Float | 1.4M |
| Short Ratio | 0 |
| % Held by Insiders | 2.51% |
| % Held by Institutions | 1.81% |
| Shares Short | 1.53K |
| Short % of Float | 0.11% |
| Short % of Shares Outstanding | 0.11% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:25 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2023 |
| Most Recent Quarter (mrq) | June 30, 2024 |
| Next Fiscal Year End | December 31, 2024 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -53.99% |
| Return on Equity (ttm) | -119.82% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -6733092 USD |
| Net Income Avi to Common (ttm) | -6464335 USD |
| Diluted EPS (ttm) | -8.73 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 3.27M USD |
| Total Cash Per Share (mrq) | 2.27 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.982 |
| Book Value Per Share (mrq) | 3.705 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7686402 USD |
| Levered Free Cash Flow (ttm) | -6133413 USD |
Profile of Salarius Pharmaceuticals
| Country | United States |
| State | TX |
| City | Houston |
| Address | 2450 Holcombe Boulevard |
| ZIP | 77021 |
| Phone | 832 834 9144 |
| Website | https://www.salariuspharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 2 |
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
Q&A For Salarius Pharmaceuticals Stock
What is a current SLRX stock price?
Salarius Pharmaceuticals SLRX stock price today per share is 0.73 USD.
How to purchase Salarius Pharmaceuticals stock?
You can buy SLRX shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Salarius Pharmaceuticals?
The stock symbol or ticker of Salarius Pharmaceuticals is SLRX.
Which industry does the Salarius Pharmaceuticals company belong to?
The Salarius Pharmaceuticals industry is Biotechnology.
How many shares does Salarius Pharmaceuticals have in circulation?
The max supply of Salarius Pharmaceuticals shares is 2.13M.
What is Salarius Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Salarius Pharmaceuticals PE Ratio is now.
What was Salarius Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Salarius Pharmaceuticals EPS is -5.79 USD over the trailing 12 months.
Which sector does the Salarius Pharmaceuticals company belong to?
The Salarius Pharmaceuticals sector is Healthcare.
Salarius Pharmaceuticals SLRX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Capital Market Composite RCMP | 102.15 USD — |
-0.54
|
— — | 101.35 USD — | 102.39 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}